Page last updated: 2024-10-15

inosinic acid

Description

Inosine Monophosphate: Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135398640
CHEMBL ID1207374
CHEBI ID17202
SCHEMBL ID19255
MeSH IDM0011370

Synonyms (73)

Synonym
30918-54-8
2'-inosine-5'-monophosphate
hypoxanthosine 5'-monophosphate
CHEBI:17202 ,
brn 0630517
einecs 205-045-1
inosine-5'-monophosphoric acid
inosine 5'-monophosphoric acid
inosine 5' monophosphate
[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-1h-purin-9-yl)tetrahydrofuran-2-yl]methyl dihydrogen phosphate
5'-inosinate
inosine 5'-monophosphate
inosinic acid
ribosylhypoxanthine monophosphate
inosine 5'-phosphate
IMP ,
inosine monophosphate
5'-inosinic acid
5'-imp
5'-inosine monophosphate
131-99-7
C00130
1P19
DB04566
1YFZ
cytosine inosinate
1QK4
1G9S
1P17
1Z6D
BB128E2C-BC89-4360-B0A0-190DDF5C0B57
BMSE000175
inosine-5'-monophosphate
tao7us05g5 ,
unii-tao7us05g5
AKOS015918470
AKOS015896456
i-5'-p
CHEMBL1207374
gtpl5124
bdbm19254
[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methyl dihydrogen
{[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-6,9-dihydro-3h-purin-9-yl)oxolan-2-yl]methoxy}phosphonic acid
SCHEMBL19255
inosine phosphate
ins-630
inosine 5'-(dihydrogen phosphate)
ins no.630
inosinic acid, 5'-
hypoxanthine riboside-5-phosphoric acid
inosinic acid [mi]
cytosine inosinate [who-dd]
e-630
[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-1h-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
W-108320
acid, inosinic
{[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-oxo-6,9-dihydro-1h-purin-9-yl)oxolan-2-yl]methoxy}phosphonic acid
((2r,3s,4r,5r)-3,4-dihydroxy-5-(6-hydroxy-9h-purin-9-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate
AKOS030494380
A1-01972
inosinsaure
25249-22-3
HY-108213
[3h]inosine monophosphate
Q27074273
5'-imp; imp; inosine 5'-(dihydrogen phosphate)
CS-0027540
F81515
DTXSID80948097
AS-56817
inosine 5 inverted exclamation marka-monophosphate
[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-hydroxypurin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
cid 5280323

Effects

ExcerptReference
"Inosinic acid (IMP) has been prepared by the deamination of adenosine monophosphate (AMP) with an immobilized adenosine (phosphate) deaminase extracted from the snail Biomphalaria glabrata. "( IMP synthesis using immobilized adenosine (phosphate) deaminase.
Accioly, LG; Carvalho Júnior, LB; Oliveira, EA; Silva, MP, 1988
)

Toxicity

ExcerptReference
" Changes in such fingerprint profiles can be used to characterize the effects of toxic insult in in vivo systems."( Metabonomic assessment of toxicity of 4-fluoroaniline, 3,5-difluoroaniline and 2-fluoro-4-methylaniline to the earthworm Eisenia veneta (Rosa): identification of new endogenous biomarkers.
Bailey, NJ; Bundy, JG; Gavaghan, CL; Hankard, PK; Lenz, EM; Lindon, JC; Nicholson, JK; Osborn, D; Sanders, I; Speir, P; Spurgeon, D; Svendsen, C; Tang, H; Trauger, SA; Weeks, JM, 2002
)
" At LC50, CINA was the most toxic (0."( In vitro safety assessment of food ingredients in canine renal proximal tubule cells.
Jeffery, B; Koči, J; Monteiro-Riviere, NA; Riviere, JE, 2015
)
"This study sought to characterize users' perceptions of, and identify the average time needed to complete a newly abbreviated version of the Institute for Safe Medication Practices Medication Safety Self Assessment for Community and Ambulatory Pharmacy (MSSA-CAP)."( Characterizing perceptions of an abbreviated ISMP Medication Safety Self Assessment for community pharmacies.
Christakos, E; Gernant, SA; Kurzatkowski, A; McCarthy, KR,
)

Bioavailability

ExcerptReference
" The absorption rate in the most proximal segment of intestinal loop was the highest."( The nucleotide derivatives inosine and inosinic acid inhibit intestinal absorption of mizoribine in rats.
Fujioka, N; Nakanishi, T; Nakashima, M; Okada, M; Suzuki, K, 2006
)

Dosage Studied

ExcerptReference
" The dosage of inosine required for protection is very high because of the rapid metabolism of inosine in vivo."( The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes.
Mabley, JG; Murthy, KG; Pacher, P; Salzman, AL; Southan, GJ; Szabo, C; Williams, W, 2008
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
inosine phosphate
purine ribonucleoside 5'-monophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (28)

PathwayProteinsCompounds
superpathway of adenosine nucleotides de novo biosynthesis I614
inosine 5'-phosphate degradation013
superpathway of purine nucleotides de novo biosynthesis I1232
inosine-5'-phosphate biosynthesis II115
guanosine ribonucleotides de novo biosynthesis215
adenosine nucleotides degradation I327
adenosine ribonucleotides de novo biosynthesis311
superpathway of purines degradation in plants745
ureide biosynthesis220
purine nucleotides degradation I (plants)334
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
IMP + H2O = 5'-Phospho-ribosyl-4-carboxamido-5-formamido-imidazole ( Purine nucleotides and Nucleosides metabolism )13
IMP + Pyrophosphate = Hypoxanthine + D-5-Phospho-ribosyl 1-diphosphate ( Purine nucleotides and Nucleosides metabolism )14
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
adenine and adenosine salvage III012
salvage pathways of purine nucleosides021
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
salvage pathways of adenine, hypoxanthine, and their nucleosides023
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
purine nucleotides de novo biosynthesis II033
salvage pathways of purine nucleosides I027
Ureide biosynthesis017
Biochemical pathways: part I0466
Nucleotide metabolism03
Metabolic reprogramming in colon cancer029
ureide biogenesis417

Protein Targets (14)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Hypoxanthine PhosphoribosyltransferaseEscherichia coliKi247.0000247.0000386.5000526.0000AID977610
Chain A, HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASEEscherichia coliKi247.0000247.0000386.5000526.0000AID977610
Chain A, Hypoxanthine-guanine phosphoribosyltransferaseCaldanaerobacter subterraneus subsp. tengcongensis MB4Ki45.000045.000045.000045.0000AID977610
Chain A, Ribonuclease pancreaticBos taurus (cattle)Ki4,600.000046.00002,323.00004,600.0000AID977610
Chain A, Ribonuclease pancreaticBos taurus (cattle)Ki4,600.000046.00002,323.00004,600.0000AID977610
Hypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)Ki5.40000.60005.54678.9800AID1226509
Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)Ki0.25000.00600.12620.2600AID92603
Inosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)Ki0.25000.03300.16540.3300AID92603
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, hypoxanthine phosphoribosyltransferaseTrypanosoma cruziKd788.400076.8000788.40001,500.0000AID977611
Chain A, hypoxanthine phosphoribosyltransferaseTrypanosoma cruziKd788.400076.8000788.40001,500.0000AID977611
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASEToxoplasma gondii RHKd61.00007.100034.050061.0000AID977611
Chain B, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASEToxoplasma gondii RHKd61.00007.100034.050061.0000AID977611
Chain A, HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASEToxoplasma gondii RHKd61.00007.100034.050061.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
T cell mediated cytotoxicityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
response to amphetamineHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine nucleotide biosynthetic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine ribonucleoside salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
locomotory behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
striatum developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cerebral cortex neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
central nervous system neuron developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
positive regulation of dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP catabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
adenine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
lymphocyte proliferationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dendrite morphogenesisHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein homotetramerizationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopaminergic neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
response to UVInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
protein homotetramerizationInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
purine nucleotide biosynthetic processInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
GMP biosynthetic processInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
GTP biosynthetic processInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
circadian rhythmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
lymphocyte proliferationInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cellular response to interleukin-4Inosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
'de novo' XMP biosynthetic processInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
GMP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
GTP biosynthetic processInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
nucleotide bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
magnesium ion bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
single-stranded DNA bindingInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
ATP bindingInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
oxidoreductase activityInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
identical protein bindingInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
metal ion bindingInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
guanosine tetraphosphate bindingInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
C-rich single-stranded DNA bindingInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
nucleotide bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
protein bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleotide bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleic acid bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
DNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
RNA bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
metal ion bindingInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
IMP dehydrogenase activityInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
cytoplasmHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
protein-containing complexInosine-5'-monophosphate dehydrogenaseEscherichia coli K-12
extracellular regionInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
peroxisomal membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
membraneInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular exosomeInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 2Homo sapiens (human)
extracellular regionInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
nucleusInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytosolInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
secretory granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
azurophil granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
ficolin-1-rich granule lumenInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
cytoplasmInosine-5'-monophosphate dehydrogenase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004Journal of molecular biology, Jan-23, Volume: 335, Issue:4
Interactions at the dimer interface influence the relative efficiencies for purine nucleotide synthesis and pyrophosphorolysis in a phosphoribosyltransferase.
AID1811Experimentally measured binding affinity data derived from PDB2004Journal of molecular biology, Jan-23, Volume: 335, Issue:4
Interactions at the dimer interface influence the relative efficiencies for purine nucleotide synthesis and pyrophosphorolysis in a phosphoribosyltransferase.
AID1226508Inhibition of Mycobacterium tuberculosis HGPRT2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.
AID92482Ability to inhibit Inosine-5'-monophosphate dehydrogenase isolated from Escherichia coli1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Inhibitors of inosinic acid dehydrogenase. 2-Substituted inosinic acids.
AID1226509Inhibition of human HGPRT2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.
AID1226510Inhibition of Escherichia coli HGPRT2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
First Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis Activity.
AID92479Inhibition of inosine monophosphate dehydrogenase in Escherichia coli1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Inhibition of inosinic acid dehydrogenase by 8-substituted purine nucleotides.
AID767228Binding affinity to Escherichia coli HPRT2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agents.
AID92603Inhibitory activity against Inosine-5'-monophosphate dehydrogenase2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005The FEBS journal, Aug, Volume: 272, Issue:15
The binding of IMP to ribonuclease A.
AID1811Experimentally measured binding affinity data derived from PDB2005The FEBS journal, Aug, Volume: 272, Issue:15
The binding of IMP to ribonuclease A.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Journal of molecular biology, May-20, Volume: 348, Issue:5
Alternative IMP binding in feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase from Thermoanaerobacter tengcongensis.
AID1811Experimentally measured binding affinity data derived from PDB2005Journal of molecular biology, May-20, Volume: 348, Issue:5
Alternative IMP binding in feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase from Thermoanaerobacter tengcongensis.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1999Biochemistry, Nov-02, Volume: 38, Issue:44
Crystal structures of the Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase-GMP and -IMP complexes: comparison of purine binding interactions with the XMP complex.
AID1811Experimentally measured binding affinity data derived from PDB1999Biochemistry, Nov-02, Volume: 38, Issue:44
Crystal structures of the Toxoplasma gondii hypoxanthine-guanine phosphoribosyltransferase-GMP and -IMP complexes: comparison of purine binding interactions with the XMP complex.
AID1811Experimentally measured binding affinity data derived from PDB2002Protein science : a publication of the Protein Society, Jul, Volume: 11, Issue:7
Crystal structures of free, IMP-, and GMP-bound Escherichia coli hypoxanthine phosphoribosyltransferase.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2002Protein science : a publication of the Protein Society, Jul, Volume: 11, Issue:7
Crystal structures of free, IMP-, and GMP-bound Escherichia coli hypoxanthine phosphoribosyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,047)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990361 (34.48)18.7374
1990's273 (26.07)18.2507
2000's198 (18.91)29.6817
2010's166 (15.85)24.3611
2020's49 (4.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials29 (2.67%)5.53%
Reviews40 (3.68%)6.00%
Case Studies8 (0.74%)4.05%
Observational1 (0.09%)0.25%
Other1,008 (92.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]